A trial for advanced small cell lung cancer with weight loss
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of nanocrystalline megestrol (a medicine to improve appetite and weight) with standard chemotherapy and immunotherapy as a first treatment for people with extensive-stage small cell lung cancer who have lost weight or have early signs of cachexia (wasting syndrome). The goal is to see if this approach can help you feel better and live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer and have not had chemotherapy for it before.
- You are between 18 and 75 years old.
- You have lost weight recently (at least 5% in the last 6 months) or have some weight loss with other signs like loss of appetite or high inflammation levels.
- Your cancer can be measured on scans (at least one tumor that can be seen on imaging).
- You have good organ function, including enough blood cells, healthy kidneys, liver, heart, and lungs.
- You are willing to follow study procedures and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different treatments based on the genetic and molecular features of your tumor. It is for people with stage IV small cell lung cancer that has returned after initial chemotherapy.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.
This trial tests a medicine called nanocrystalline megestrol acetate to help people with advanced small cell lung cancer who have lost weight and appetite. The goal is to see if the drug can improve their condition.
This trial tests whether a medicine called megestrol acetate can help improve appetite and weight in people with advanced lung cancer who are malnourished. It's for those who haven't had chemotherapy for their advanced cancer yet.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.